Outcomes of Rapid Restart Among People With Previously Diagnosed HIV at a Safety-Net HIV Clinic in San Francisco

旧金山一家安全网艾滋病诊所对先前已确诊艾滋病毒感染者进行快速重启治疗的结果

阅读:2

Abstract

BACKGROUND: Little is known about outcomes of rapid restart of antiretroviral therapy (ART) among people with HIV relinking to care. SETTING: Safety-net HIV clinic in San Francisco. METHODS: Using electronic medical record data, we conducted a retrospective study of adults with HIV (≥18 years old, out of care, self-reported off ART) seen for rapid (same-day) restart of ART. Descriptive statistics summarized baseline sociodemographic and clinical variables. χ 2 and Fisher exact tests assessed associations between sociodemographic or clinical variables and 2 primary outcomes: (1) viral suppression (VS) [HIV viral load (VL) <200 copies/mL] within 180 days and (2) sustained re-engagement in care (≥1 primary care provider visit both within 90 and 91-180 days after rapid restart). Complete case VS analysis included those with baseline viremia and follow-up HIV VLs. In sensitivity analysis, those with missing follow-up VLs were considered nonsuppressed. RESULTS: Between August 2020-October 2023, 141 adults (median age 42; 85% cis-male; 26% Latino/a) presented for rapid restart. Housing instability/homelessness (46%), substance use (61%), and mental illness (49%) were common. Among those with baseline viremia who returned for follow-up VLs, VS was attained in 79% and associated significantly with non-Latino/a ethnicity (87% non-Latino/a vs. 57% Latino/a, P = 0.004). However, VS was 58% when considering missing follow-up VLs as nonsuppressed. Sustained re-engagement in care was observed in only 33%. CONCLUSION: After rapid restart, sustained re-engagement in care and VS were low. Evaluation of key processes of rapid restart, retention efforts, and studies on effective re-engagement support strategies are needed.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。